- CordenPharma has been selected as a Supplier Partner in the Pharmaceutical Supply Chain Initiative (PSCI)as of March 2025.
- The selection follows an assessment of CordenPharma’s adherence to PSCI’s five responsible business practices, particularly in high-potency compound handling, safety programs, and risk management.
CordenPharma has been chosen as a Supplier Partner in the Pharmaceutical Supply Chain Initiative (PSCI), joining the programme’s second cohort in March 2025. The selection follows the company’s successful fulfilment of PSCI’s supplier partnership requirements.
PSCI is a non-profit association that unites pharmaceutical and healthcare companies committed to responsible supply chain management. Its standards focus on ethics, labour practices, health and safety, environmental responsibility, and management systems. The PSCI audit programme evaluates suppliers based on these key principles to ensure safe working conditions, sustainable practices, and economic development.
During the assessment phase, CordenPharma demonstrated strengths in several critical areas, including high-potency compound handling, behaviour-based safety (BBS) programmes, and risk management. These capabilities contributed to its recognition as a qualified PSCI supplier partner.
The partnership aligns with CordenPharma’s commitment to sustainability and responsible procurement. It also supports customer audit requirements while reinforcing the company’s broader environmental and safety goals.
William Cashin, Chief Quality & Compliance Officer at CordenPharma, stated: “I am proud of the hard work across our global teams on sustainability. Our employees are delighted to achieve supplier partnership status and to demonstrate our commitment to the PSCI Principles. We look forward to sharing future audit results and Maturity Models with transparency and collaborating with customer PSCI members towards our common goal.”
